高级检索
当前位置: 首页 > 详情页

Gender differences in the burden of multiple sclerosis in China from 1990 to 2019 and its 25-year projection: An analysis of the Global Burden of Diseases Study

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ ESCI

机构: [1]Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Ophthalmol, Beijing, Peoples R China [2]Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing, Peoples R China [3]Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Ophthalmol, 1 Shuaifu Yuan, Beijing 100730, Peoples R China
出处:

关键词: disability-adjusted life years disease burden gender multiple sclerosis prediction

摘要:
Background and AimsMultiple sclerosis (MS) is a crippling, chronic, gender-related disease that causes burdens to individuals and society. China has a considerable and increasing population of MS. We aim to analyze the gender disparities in the burden of MS in China and predict the trends.MethodsThe study was conducted based on the Global Burden of Disease Study 2019. Data on incidence, prevalence, deaths, and disability-adjusted life years (DALYs) of MS in China from 1990 to 2019 was descriptively analyzed by year, gender, and age group. The Nordpred package in R (version 4.2.2) was used for age-period-cohort analysis to predict the all-ages numbers and age-standardized rates of incidence, prevalence, deaths, and DALYs in China from 2020 to 2044.ResultsThe number of prevalent cases of MS in 2019 reached 18,143.56 (95% uncertainty intervals [UI]: 13,997.71-22,658.60) in males and 24,427.11 (95% UI: 18,906.02-30,530.21) in females in China. The peak age of prevalence was shifted from 40-44 years in 1990 to 45-49 years in 2019 in females but remained unchanged in males. In contrast to the increased age-standardized prevalence rate, the age-standardized death rate (ASDR) and age-standardized DALYs rate showed downward trends, which were more significant in females. Different from the global, Chinese males showed lower prevalence but higher deaths and DALYs than females for age-standardized rates and numbers. In the next 25 years, the patient population will remain large and peak around 44,599.78 in 2025-2029. The ASDR, age-standardized DALYs rate, and DALYs number were expected to decrease. The improvements in deaths and DALYs will be more significant in females.ConclusionMales with MS had a lower prevalence but higher deaths and DALYs than females in China. The ASDR and age-standardized DALYs rate have reduced over the past 30 years and were expected to continue decreasing, especially in females. The burden of MS will remain notable in the next 25 years.

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2022]版:
最新[2025]版:
大类 | 4 区 医学
小类 | 3 区 医学:内科 4 区 公共卫生、环境卫生与职业卫生
JCR分区:
出版当年[2021]版:
最新[2023]版:
Q2 MEDICINE, GENERAL & INTERNAL Q2 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH

影响因子: 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者:
第一作者机构: [1]Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Ophthalmol, Beijing, Peoples R China
通讯作者:
通讯机构: [1]Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Ophthalmol, Beijing, Peoples R China [3]Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Ophthalmol, 1 Shuaifu Yuan, Beijing 100730, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

相关文献

[1]Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019 A Systematic Analysis for the Global Burden of Disease Study 2019 [2]The burden of injury in Central, Eastern, and Western European sub-region: a systematic analysis from the Global Burden of Disease 2019 Study [3]Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study. [4]Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019. [5]Global, regional, and national prevalence, disability adjusted life years, and time trends for refraction disorders, 1990-2019: findings from the global burden of disease study 2019 [6]Chinese and Global Burdens of Gastrointestinal Cancers From 1990 to 2019 [7]Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 [8]Trends and cross-country inequalities in the global burden of osteoarthritis, 1990-2019: a population-based study [9]Global burden of benign prostatic hyperplasia, urinary tract infections, urolithiasis, bladder cancer, kidney cancer, and prostate cancer from 1990 to 2021 [10]Global, regional, national burden and gender disparity of cataract: findings from the global burden of disease study 2019

资源点击量:25471 今日访问量:0 总访问量:1498 更新日期:2025-06-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)